PCM
PLSE icon

Portolan Capital Management’s Pulse Biosciences PLSE Stock Holding History

Portolan Capital Management’s Portfolio PLSE Stock Details PLSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.8M Buy
733,372
+339,873
+86% +$6.27M 0.84% 40
2025
Q4 		$5.4M Buy
393,499
+291,302
+285% +$4.54M 0.29% 102
2025
Q3 		$1.81M Buy
+102,197
New +$1.62M 0.1% 108

Other funds holding PLSE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Portolan Capital Management's PLSE Position: Q1 2026 in Review

Portolan Capital Management increased its Pulse Biosciences (PLSE) stake by 86% in Q1 2026, buying an estimated $6.27M and bringing the position to 733,372 shares worth $15.8M. The position accounts for 0.84% of the portfolio, ranked #40.

Portolan Capital Management first reported a position in PLSE in Q3 2025 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold PLSE as of Q1 2026.

  • Portolan Capital Management held 733,372 shares of Pulse Biosciences worth $15.8M as of Q1 2026.
  • Portolan Capital Management bought 339,873 Pulse Biosciences shares in Q1 2026, an estimated $6.27M.
  • Pulse Biosciences made up 0.84% of Portolan Capital Management's portfolio in Q1 2026, its #40 holding.
  • Portolan Capital Management first reported a position in Pulse Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 96 funds tracked by Wall St. Rank held Pulse Biosciences as of Q1 2026.

Based on Portolan Capital Management's 13F filing for Q1 2026, filed 15 May 2026.